Here are four observations:
1. The increasing interest in tissue-engineered and stem cell products will boost the market’s growth.
2. Regenerative medicines’ potential in restoring diseased organs will elevate the market.
3. Cell therapy captured 80 percent of the U.S. regenerative medicine market in 2015.
4. Dominate market vendors include Acelity, Mesoblast, Organogenesis, Reprocell and Stryker.
More articles on biologics:
Smith & Nephew to purchase regenerative medicine company for $210M: 3 points
Anika Therapeutics appoints new chief human resources officer: 5 points
Dr. Alok Sharan presents results of novel surgical procedure at the NuVasive Spine Summit
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
